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Metastatic breast cancer subtypes and central nervous system metastases 
C. Aversa, V. Rossi, E. Geuna, R. Martinello, A. Milani, S. Redana, G. Valabrega, M. Aglietta, F. Montemurro 
Abstract 
Background: Breast cancer (BC) subtypes have different survival and response to therapy. We studied 
predictors of central nervous system metastases (CNS-M) and outcome after CNS-M diagnosis according to 
tumor subtype. 
Patients and methods: 488 patients with diagnosis of metastatic BC were retrospectively evaluated. 
According to the combination of hormone receptors (HR) and HER2 status, tumors were grouped in: 
Luminal (Lum), Luminal/HER2+, pure HER2-positive (pHER2+) and triple negative (TN). Time to CNS 
progression, CNS-M free interval and Overall Survival (OS) after CNS-M occurrence were compared by the 
log-rank test. Cox-proportional hazard models were used to study predictor factors associated with CNS 
progression, including tumor subtype and all potentially clinical relevant variables. 
Results: 115 patients (pts) developed CNS-M with a median time to CNS progression of 31 months. The rate 
of CNS-M by subtype was: Lum 14%, Lum/HER2+ 35%, pHER2+ 49%, TN 22% (p < 0.001). Compared with 
Lum tumors, Lum/HER2+ (HR 2.514, p < 0.001), pHER2+ (HR 6.799, p < 0.0001) and TN 
(HR = 3.179,p < 0.001) subtypes were at higher risk of CNS-M. Median OS in months after CNS-M was: Lum 
7.4, Lum/HER2+ 19.2, pHER2+ 7, TN 4.9 (p < 0.002). Belonging to the Lum/HER2+ subtype (HR 
0.48,p < 0.037) and having isolated CNS (HR 0.37, p < 0.004) predicted significantly reduced risk of death. 
Conclusions: After CNS-M, the Lum/HER2+ subtype appears associated with the longest OS. Prospective 
clinical trials would be required for evaluating the potential role of screening for asymptomatic CNS lesions 
and of more aggressive CNS-M treatment in Lum/HER2+ subtype. 
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Introduction 
The incidence of symptomatic central nervous system metastases (CNS-M) in women with breast cancer 
(BC) was reported in the range of 10%–16% in historical series [1] and [2]. While these figures referred to 
CNS-M presenting clinically during the course of metastatic disease, the real incidence of this metastatic 
localization has been known to be higher. In fact, on account of autopsy series, rates as high as 30% in 
patients dying from BC without clinically overt CNS-M have been reported [1] and [3]. Indeed, CNS-M 
generally occur as a late event in the natural history of metastatic BC. For this reason, and since the 
improvement in systemic treatments contrasts with the relative lack of efficacy of antitumor agents in the 
CNS, the incidence of clinically overt CNS-M seems to have raised significantly in the last two decades [4]. 
As a consequence, the optimal management of patients at risk of, or with diagnosed CNS-M is an unmet 
medical need and a major focus for research [4]. The prognosis of patients with CNS-M is, in fact poor, with 
survival rates of only 20% at one year from first diagnosis and less than 2% at two years [5]. Furthermore, 
CNS involvement is often associated with neurological complications that have a major impact on patients' 
quality of life. [4] There is increasing recognition that breast cancer is a collection of heterogeneous 
diseases. A seminal paper by Perou and colleagues has revealed that at least 4 major breast cancer 
subtypes can be identified based on distinct gene expression patterns [6]. Although more recent work in 
the field has added complexity to this classification [7], it is clear that tumor subtype influences all aspects 
of the natural history, pattern of relapse and response to treatments of breast cancer [8]. Indeed, single 
biological factors as estrogen receptor (ER) and/or progesterone receptor (PgR) status and human 
epidermal growth factor receptor 2 (HER2) overexpression have proven to be associated the risk of 
developing CNS-M in the past [9], [10] and [11]. These immunohistochemical (IHC) markers may be 
combined to achieve a reasonable approximation of the molecularly defined subtypes [12]. Consequently, 
several authors have recently analyzed the impact of breast cancer subtype defined by ICH on incidence of 
CNS-M and subsequent survival [13], [14], [15], [16] and [17]. Overall, these analyses identify the triple-
negative (ER and PgR and HER2 negative) and the HER2-positive subsets as those at the highest risk of CNS-
M. However, while overall survival is shortest for triple-negative breast cancer, it results particularly long, 
usually in the range of 15–17 months, in HER2-positive patients, especially when systemic treatment is 
feasible after the diagnosis of CNS-M [13], [14], [15], [16], [17], [18], [19], [20] and [21]. Differently from 
what thought in the relatively recent past, heterogeneity of HER2-positive tumors according to HR 
expression has now been fully recognized [22], [23] and [24]. Both the HER2 and the HR pathway concur to 
the peculiar biology of this distinct entity and to its clinical behavior in adjuvant and metastatic setting. 
With these premises we sat out to analyze predictors of CNS-M and the outcome after CNS recurrence 
according to tumor IHC-defined subtypes, with a focus on possible differences in the HER2-positive subset 
according to hormone receptor status. 
Material and methods 
Clinical records of 488 patients starting first-line chemotherapy for metastatic disease between June 1999 
and March 2012 were identified from the medical charts of our Outpatient Clinic. All patients with HER2-
positive disease received anti-HER2 treatment in addition to chemotherapy for metastatic disease. Median 
follow-up was 34 months (2–210 months). For each patient we collected the following data: date of first 
breast cancer diagnosis, stage at first diagnosis, ER and/or PgR expression, HER2 status, 
neoadjuvant/adjuvant chemotherapy and/or hormone therapy, exposure to anthracycline or taxanes as 
adjuvant treatment, exposure to endocrine therapy as adjuvant treatment and/or for metastatic disease, 
date and site of first metastatic recurrence, first chemotherapy or trastuzumab based treatment for HER2-
positive disease, date of further metastatic recurrences, date of the first CNS-M diagnosis, treatments for 
CNS-M, status at last follow-up date or date of death. According to the combination of HR and HER2 status, 
tumors were grouped as follows: Luminal (Lum): HR+ (i.e. ER+ and/or PgR+)/HER2−, Luminal/HER2+ 
(Lum/HER2+): HR+/HER2+, pure HER2-positive (pHER2+): HR−/HER2+, and triple negative (TN): HR−/HER2−. 
ER and PgR status was determined by immunohistochemical (IHC) analysis, with 1% cut off for positive 
result according to current guidelines [25]. The HER2 status determined by immunohistochemical (IHC) 
staining by the Dako HercepTest, with a 3+ score identifying positive cases. Uncertain results (2+ at IHC) 
were further analyzed with fluorescent in situ hybridization (FISH). A HER2/Cep17 ratio ≥2 was chosen to 
define HER2 amplification. 
Statistical analyses 
Comparisons between categorical variables were accomplished by the Fisher's or the Chi-square test, as 
appropriate. The following end points were evaluated by Kaplan Meier analysis: overall survival (OS), which 
was calculated from the date of first metastatic diagnosis to the date of death or last follow-up for alive 
patients; time to CNS progression, which was calculated from the date of the first diagnosis of metastatic 
breast cancer to that of the first documented CNS-M or last follow-up in patients without CNS-M; CNS-M 
free interval, which was calculated from the date of the first diagnosis of metastatic breast cancer to that of 
the first documented CNS-M restricted to patients who developed the event: OS after CNS-M, which was 
calculated from the date of the first CNS-M diagnosis to date of death or last follow-up for alive patients. 
Kaplan Meier curves were compared by the log-rank test. Factors associated with CNS progression and OS 
after CNS-M were evaluated by Cox hazard analysis where the effect of tumor subtype was analyzed 
together with that of other potentially relevant clinical variables. These included: age at diagnosis of 
metastatic breast cancer, stage at first diagnosis, disease free survival (from first localized disease to 
metastatic progression), exposure to adjuvant chemotherapy and to neoadjuvant or adjuvant regimens 
containing anthracyclines and/or taxanes, pattern and number of metastatic sites, and type of first-line 
chemotherapy or trastuzumab containing treatment. Because of the relatively small number involved and 
the exploratory nature of this analysis, we did not test for multiple comparisons. Statistical analyses were 
performed using the SPSS software 17.0. For all analysis statistical significance was set atp < 0.05. 
Results 
Patients and overall survival from the first diagnosis of metastatic disease 
A total of 488 metastatic BC patients receiving chemotherapy between June 1999 and March 2012 were 
analyzed and Table 1 summarizes their relevant demographic characteristics. Median age at first breast 
cancer diagnosis was 51 years and median age at first metastatic recurrence was 55 years. A total of 267 
(55%), 75 (15%), 79 (16%) and 64 (13%) patients had Lum, Lum/HER2+, pHER2+ and TN cancers, 
respectively. In 3 (1%) patients the tumor subtype could not be determined. A total of 249 (51%) patients 
had received adjuvant chemotherapy and 274 (56%) had received adjuvant hormonal therapy. Of the 154 
patients with HER2-positive disease, a total of 15 (10%) who underwent breast cancer surgery after 
September 2005 (when adjuvant trastuzumab was registered for adjuvant use in Italy), received adjuvant 
trastuzumab added to chemotherapy. 
Table 1: Main characteristics of patients study group. 
Variable N % 
Total (n = 488)  
Median age at first BC diagnosis (years range) 51 (22–83)  
Median age at first metastatic recurrence (years range) 55 (24–85)  
Stage at first metastatic BC diagnosis 
 I/II 222 46 
 III 138 28 
 IV 104 21 
 Unknown stage 24 5 
Hormone receptor status 
 ER + e PgR+ 235 48 
 ER + e PgR− 88 18 
 ER- e PgR+ 8 2 
 ER- e PgR− 143 29 
 Unknown 14 3 
HER2 status 
 Positive 154 32 
 Negative 334 68 
Biological subgroup 
 Lum 267 55 
 Lum/HER2+ 75 15 
 pHER2 79 16 
 TN 64 13 
 Unknown 3 1 
Adjuvant chemotherapy 249 51 
Variable N % 
Adjuvant hormonotherapy 274 56 
Median disease-free survival (months range) 28 (0–311)  
First metastatic sites 
 Liver 243 50 
 Lung 155 32 
 Bone 312 64 
 Soft tissue/lymphnodes 293 60 
 Effusion 65 13 
 Brain 23 5 
Visceral involvement at first diagnosis of metastases 327 67 
Number of metastatic sites at first diagnosis of metastases 
 One 141 29 
 Two 127 26 
 Three or more 220 45 
Median time to the first BC metastasis from the diagnosis of EBC (months, range) 28 (0–306)  
Median time to CNS from the diagnosis of EBC (months, range) 64 (3–350)  
Median time to CNS progression from the first diagnosis of BC metastasis (months, range) 31 (0–192)  
 Lum/HER2+ 96 (64–129)  
 pHER2+ 32 (0–74)  
BC = breast cancer ER = estrogen receptor PgR = progesterone receptor EBC = early breast cancer. 
Table 2 summarizes the types of first-line chemotherapy received by patients. All patients with HER2-
positive metastatic BC received trastuzumab-based treatment, with most of them receiving continuous 
trastuzumab beyond disease progression, in combination with alternative chemotherapy agents or 
hormonal therapy. At the time of the analysis, 343 patients had died because of disease progression. The 
median OS from first metastatic progression was 40.5 months (95% C.I. 37.2–43.8). Fig. 1 shows the Kaplan 
Meier curves of OS according to subtype. Median OS for patients with Lum, Lum/HER2+, p-HER2+ and TN 
tumors was 44.4 months (95% 37.7–51.2), 55.3 months (95% C.I. 37.4–73.3), 35.9 months (95% C.I. 29.7–
42.1) and 27.1 months IC (95% C.I. 22.6–31.6), respectively (overall log-rank test, p = 0.0001). 
 
Table 2: First line chemotherapy treatment. 
 
Treatment N % 
Containing taxanes (no anthracylines) 267 55 
Containing anthracyclines (with or without taxanes) 14 3 
Containing vinorelbine 95 20 
Capecitabine 42 9 
Other treatmentsa 35 7 
a    In 30 patients with Lum/HER2+ tumors the hormonal therapy was the first treatment. In 5 patients details of the first line of therapy 
were unknown. 
 
 Fig. 1. Kaplan Meier curve estimates of overall survival probability according to biological subgroup. 
Red, Lum/HER2+; blue, Lum; purple, pHER2+; green, TN 
CNS progression and subsequent outcome 
At the time of the analysis 115 patients (24%) had developed CNS-M. In all cases CNS-M were diagnosed 
following CNS imaging performed because of neurological symptoms. The proportion of CNS-M in each 
tumor subtype was: 14%, 35%, 49%, and 22% in Lum, LUM/HER2+, pHER2+ and TN tumors, respectively 
(Table 3, p < 0.001). Isolated CNS-M (no concomitant disease progression in sites outside the CNS) occurred 
in 30 pts (26%). This pattern of relapse was observed more frequently in patients with HER2-positive 
tumors [13 pts (43%) in Lum/HER2+ and 13 pts (43%) in pHER2+] compared to the other subgroups [2 pts 
(7%) in Lum and 2 pts (7%) in TN, p < 0.0001)]. Most of the patients with isolated CNS-M received whole 
brain radiotherapy (17 pts). Of the remaining 13 patients with isolated CNS-M, 7 were managed with 
surgery plus radiotherapy and 6 with stereotactic radiotherapy. Most of the patients with CNS-M 
associated with extracranial progression received whole brain palliative radiation therapy with or without 
anticancer therapy (41 patients). A small group received surgery plus radiotherapy (3 pts) or stereotactic 
radiotherapy (11 pts) and the remaining 30 patients, who had extensive extra-CNS progression, received 
systemic chemotherapy alone (11 pts) or best supportive care (19 pts). In patients stratified according to 
tumor subgroup, the median time to CNS progression was not reached for Lum and TN tumors, and was 96 
months (95% C.I. 63.9–128.6) and 32 months (95% C.I. 0–73.5) for Lum/HER2+ and pHER2+ tumors, 
respectively ( Fig. 2, overall log-rank test, p < 0.0001). The overall median CNS-M free interval, restricted to 
patients who developed CNS-M, was 17.6 months (95% C.I. 14.1–21.3). According to subtypes, CNS-M free 
interval was 17 months (95% C.I. 8.7–25.3), 24.6 months (95% 14.6–34.6), 16.4 months (95% C.I. 11.8–21), 
and 9.2 months (95% C.I. 8.4–10.1) for Lum, Lum/HER2+, pHER2+ and TN tumors, respectively ( Fig. 3, 
overall log-rank test, p < 0.014). A multivariate analysis conducted in the whole dataset confirmed that, 
compared with Lum tumors, Lum/HER2+ (HR 2.514, p < 0.001), pHER2+ (HR 6.799, p < 0.0001) and TN 
(HR = 3.179, p < 0.001) subtypes were at higher risk of CNS-M. Having more than three metastatic sites 
(HR = 2.712, p < 0.0001) and stage III as initial breast cancer presentation (HR = 4.836 p < 0.0001) resulted 
also independently associated with higher risk of CNS-M. By contrast older age (HR = 0.943, p < 0.0001) was 
associated with low risk of CNS-M development; for every additional year of age of first diagnosis of 
metastatic breast cancer was observed a reduction in the risk of brain metastases of approximately 6%. 
 
Table 3: Brain metastases progression according to biological subgroup. 
 
Biological subgroup Patients with brain metastases Patients without brain metastases p 
Lum 36 (14) 231 (86) <0.001 
Lum/HER2+ 26 (35) 49 (65) 
pHER2 39 (49) 40 (51)s 
TN 14 (22) 50 (78) 
 
 
Fig. 2. Kaplan Meier curve estimates of median time to CNS progression from the first metastatic 
diagnosis in overall population. Red, Lum/HER2+; blue, Lum; purple, pHER2+; green, TN 
 
Fig. 3: Kaplan Meier curve estimates of median CNS-M free interval from the first metastatic 
diagnosis in patients developing CNS-M. Red, Lum/HER2+; blue, Lum; purple, pHER2+; green, TN 
 
 
Survival after CNS progression 
Ninety of the 115 patients developing CNS-M had died at the time of this analysis. The median overall OS 
after CNS-M was 8.8 months (95% C.I. 6.1–11.5). Fig. 4 shows OS after CNS-M according to subtype. We 
observed a median OS after CNS-M of 7.4 months (95% C.I. 4.4–10.4), 19.2 months (95% 1.9–36.5), 7 
months (95% C.I. 3.4–10.8), and 4.9 months (95% C.I. 0.0–11.1) for Lum, Lum/HER2+, pHER2+ and TN 
tumors, respectively (p < 0.002). 
 
Fig. 4: Kaplan Meier curve estimates of overall survival after CNS-M diagnosis according to 
biological subgroup. Red, Lum/HER2+; blue, Lum; purple, pHER2+; green, TN. 
 
Multivariate analysis (Table 4) revealed that belonging to the Lum/HER2+ subtype (HR 0.48 compared with 
the Lum subtype, p < 0.037) and having isolated CNS (HR 0.37, compared with CNS-M plus systemic 
progression, p < 0.004) predicted significantly reduced risk of death in patients with CNS-M. 
 
Table 4:Multivariate analysis of factors associated to survival after CNS progression. 
 
Variable HR IC 95% P 
Biological subgroup 
Lum 1   
Lum/HER2+ 0.481 0.242–0.956 0.037 
pHER2 1.093 0.634–1.884 0.749 
TN 0.741 0.372–1.480 0.396 
Isolated CNS progression 0.374 0.192–0.730 0.004 
DFS (months) 0.997 0.989–1.004 0.358 
 
DFS = disease free survival. 
 
 
Discussion 
Central nervous system involvement is an emerging medical priority in patients with breast cancer. In fact, 
in recent years, its incidence is rising, and this may be due to prolonged survival achieved by the expanding 
armamentarium of active treatments to control extracerebral disease. Indeed, in this large dataset of 488 
metastatic breast cancer patients, we observed that about one quarter of them developed CNS-M, a figure 
that is higher than previous historical reports [1] and [2]. Furthermore, we registered a median time to 
CNS-M progression of 31 months which confirms that, overall, CNS-M could be considered as a late event in 
the natural history of treated metastatic breast cancer. Interestingly, we found that women with 
Lum/HER2+ tumors developed CNS-M with a median time to the event of 96 months from the date of early 
breast cancer diagnosis, which exceeds the 55 months median OS reported for this subgroup. Intuitively, 
the longer the time during which occult CNS metastases could outgrow, the higher the incidence of this 
type of metastases. In addition, we also confirmed that women with HER2-positive metastatic disease, who 
received trastuzumab-based chemotherapy, are at the highest risk of CNS-M, but stratification according to 
hormone receptor status revealed interesting differences. Patients with Lum/HER2+ tumors had a trend to 
develop CNS-M slightly less frequently and at later times compared with those with pHER2+ tumors 
(median time to CNS progression 96 vs 32 months). Moreover, Lum/HER2+ tumors stood out as the best 
prognostic group also considering CNS-M free interval. Indeed, compared with other tumor subtypes, 
patients with Lum/HER2+ tumors had the highest median CNS-M free interval (24.6 months), probably due 
to the addition of hormonal therapy to the anti-HER2 agents in metastatic setting. At multivariate analysis, 
tumor subtype retained its independent prognostic value with respect to CNS-M, together with younger 
age at diagnosis of metastatic disease, stage III disease at first diagnosis of breast cancer, and more 
extensive metastatic disease (p < 0.001). The hazard ratio was confirmed highest for pHER2+ tumors. 
Before discussing the potential implications of our analysis, we have to acknowledge its main limitations. 
We selected patients admitted to our outpatient clinic to receive chemotherapy for metastatic disease and 
a number of them had their surgery for primary breast cancer outside our Institution. Because of missing or 
unreliable information on Ki67, our stratification into immunohistochemical subtypes does not match with 
what recommended by current guidelines [12], in particular for the ability to distinguish between luminal A 
and B/HER2-negative subtypes [26]. Furthermore, patients with Lum tumors in this series developed 
endocrine resistance at some point of their clinical course and were prescribed chemotherapy. We may 
therefore speculate that the Lum group was enriched in aggressive tumors, regardless of their initial 
subtype. This calls into the question another potential caveat, which is represented by change in the HR 
and HER2 expression during the course of metastatic progression and through different lines of treatments 
for metastatic disease. For the majority of patients, subtyping was based on determinations performed on 
the primary, rather than the metastatic tumor. A change in hormone-receptor expression has been seen to 
occur at a clinically significant rate [27]. Similar changes in hormone receptor status have been also recently 
described in papers comparing CNS-M with primary tumors, whereas HER2 status tends to remain 
stable [28] and [29]. However, the differences in proportion and time to development of CNS-M that we 
found confirm that we analyzed different clinical and biological entities. This factor becomes particularly 
relevant considering our main finding that the Lum/HER2+ subset showed the best prognosis after the 
diagnosis of CNS-M. In fact, a number of recent reports suggest that, with the availability of anti-HER2 
treatments, the survival of patients with HER2-positive tumors diagnosed with CNS-M and who are still 
amenable to medical treatment is favorable, compared with other 
subgroups [13], [14], [15], [16], [17], [18],[19], [20] and [21]. Here we found that this effect is limited to 
HER2-positive tumors that co-expressed hormone receptors (Lum/HER2+). Interestingly, pHER2+ tumors 
had a median OS after CNS-M similar to Lum and just slightly longer than TN tumors. Because of the 
growing body of data suggesting a different biology of HER2-positive disease according to HR status [24], 
we believe that the lower incidence, longer time to develop CNS-M and longer OS after CNS-M in patients 
with Lum/HER2+ tumors are unlikely to be a random finding. Recently, a few retrospective studies in breast 
cancer patients with CNS-M evaluated the incidence and clinical outcomes of CNS-M according to breast 
cancer subtypes reporting separately HER2-positive tumors according to HR 
coexpression [13], [15], [30] and [31]. While in the paper by Sperduto and colleagues the OS after CNS-M 
was similar in HER2-positive patients stratified according to hormone receptor status, Laurent-Braccini and 
colleagues found a trend similar to ours. The median OS after CNS-M was 14.9 months and 8.9 months for 
Lum/HER2+ and pHER2 tumors, respectively, although this difference was not statistically significant. In 
their analysis of 119 patients with breast cancer and CNS-M, Anders and colleagues found that the median 
OS after CNS-M was longest (1.27 years) in Lum/HER2+ tumors compared with other subtypes [13]. Finally, 
Berghoff and colleagues, who analyzed 213 women with breast cancer and CNS-M, found that the median 
brain metastasis-free interval (time from the diagnosis of extracranial metastases to that of CNS-M) was 
significantly longer according to HR status in HER2+ tumors (26 vs 15 months for HR+ and HR- tumors, 
respectively, p = 0.033) [15], another finding consistent with our results. Unfortunately, all these reports 
have methodological weaknesses. Definitions of hormone receptor positivity (cutoffs, or whether the 
primary tumor or the CNS-M, were tested) are not often detailed and centralized revision of hormone 
receptor status and HER2 was not performed in the majority of them, including our own. With these 
limitations in mind, however, we believe that evidence consistently points at a difference in the CNS-M 
behavior of HER2-positive tumors according to HR status. A deeper comprehension of the molecular basis 
of these findings could be provided by gene expression profile analysis. Metastatic colonization of different 
target organs seems to be a genetically defined, highly selective process that relies on specific properties of 
cancer cells and their interactions with organ microenvironment [32]. For example, Massagué and 
colleagues were able to identify a gene expression signature associated with breast cancer brain metastasis 
(BrMS). Among the 17 genes whose expression distinguished primary tumors with different probability of 
developing brain metastasis, 6 were shared with a 18-gene signature of lung metastasis. Intriguingly, some 
of these shared genes encoded for proteins involved in invasion and extravasation (MM1), disruption of 
endothelial junctions (ANGPTL4) and cancer cell migration (FSCN1). More importantly, by using an 
experimental model mimicking the blood–brain barrier, the authors found that the expression of COX2 and 
the genes for two EGFR ligands (HBEGF andEREG), could specifically prime breast cancer cells for 
extravasation into the brain [33]. We therefore believe that our findings may have two potential 
implications in the way we currently conceive the event of CNS-progression in breast cancer patients: first, 
for the majority of patients and regardless of their main immunohistochemical features (Lum, pHER2+ and 
TN), little progress has been made over recent years in extending survival after CNS-M, which averages 7–8 
months. In fact, CNS progression remains the main cause of death in women with metastatic breast cancer 
and CNS-M [34]. Second, the prolonged OS found in Lum/HER2+ patients would make CNS-M screening in 
asymptomatic patients an attractive option to detect early events that could be amenable to local 
therapies. By virtue of a biology where the effect of HER2 on aggressiveness is somewhat mitigated by 
concomitant HR expression, and with endocrine therapy being an additional option in the therapeutic 
armamentarium, these patients may experience unexpectedly long OS if correctly managed. It is also 
important to keep in mind that the findings presented in our series are likely to be just the tip of the 
iceberg of a potentially larger number of factors that may play an important role in promoting organ-
specific metastasis. Elucidating these mechanisms would likely result in improvement in the outlook of 
breast cancer patients either at risk of developing or with established CNS metastases. 
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